A putative hepatitis B virus sequence motif associated with hepatocellular carcinoma in South African adults
Maponga TG. et al, (2025), Annals of Hepatology, 30, 101763 - 101763
Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field
Lumley SF. et al, (2025), The Lancet Microbe, 101076 - 101076
Whole genome sequencing of hepatitis B virus using tiled amplicon (HEPTILE) and probe based enrichment on Illumina and Nanopore platforms
Lumley SF. et al, (2025), Scientific Reports, 15
A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir
Lumley SF. et al, (2024), Journal of Clinical Virology, 174, 105711 - 105711
Corrigendum to A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir.: Journal of Clinical Virology 174 (2024) 105711.
Lumley SF. et al, (2024), Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 174
Multiple risk factors for persistent HBV viraemia in an adult receiving nucleos/tide analogue therapy
Lumley S. et al, (2024), Sexually Transmitted Infections, 100, 329 - 331
Peer support for people living with hepatitis B virus—A foundation for treatment expansion
Downs LO. et al, (2024), Journal of Viral Hepatitis, 31, 490 - 499
Social, clinical and biological barriers to hepatitis B virus suppression with nucleos/tide analogue therapy: who is at risk and what should we do about it?
Im YR. et al, (2024), Sexually Transmitted Infections, 100, 259 - 263
Under-representation of the WHO African region in clinical trials of interventions against hepatitis B virus infection
Delphin M. et al, (2024), The Lancet Gastroenterology & Hepatology, 9, 383 - 392
Pan-genotypic probe-based enrichment to improve efficiency of Hepatitis B virus sequencing
Lumley SF. et al, (2023)